3SBio Inc. announced that it has entered into an exclusive licensing deal with Alteogen Inc. for the development, manufacturing and marketing of ALT-P7, a novel antibody-drug conjugate (ADC) targeting the human epidermal growth factor receptor 2 (HER2) gene pathway for cancer in Mainland China, Hong Kong and Macau. The deal included upfront, milestone and royalty payments. This is the company's first business collaboration with Alteogen.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,85,900 KRW | +3.28% | -3.73% | +88.73% |
2023 | Alteogen Inc. Announces Clinical Trial of Tergase Showed Zero Incidence of ADA | CI |
2023 | ALTEOGEN Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+88.73% | 714.13Cr | |
-2.29% | 8.99TCr | |
-3.95% | 3.76TCr | |
+63.05% | 2.65TCr | |
-22.14% | 1.43TCr | |
-7.96% | 1.3TCr | |
-9.33% | 1.19TCr | |
-46.33% | 1.08TCr | |
+5.77% | 911.12Cr | |
-17.66% | 732.39Cr |
- Stock Market
- Equities
- A196170 Stock
- News ALTEOGEN Inc.
- 3SBio Inc. Enters into an Exclusive Licensing Deal with Alteogen Inc